Skip to main content

Table 3 Association of quartiles of time-averaged markers oxidative stress with mean ESA resistance index (ERI) over 6-month follow-up in maintenance hemodialysis patients

From: Association of plasma F2-isoprostanes and isofurans concentrations with erythropoiesis-stimulating agent resistance in maintenance hemodialysis patients

 

Concentration

Model 1a

Model 2b

Model 3c

β

95 % CI

P-valued

β

95 % CI

P-valued

β

95 % CI

P-valued

F2-Isoprostanes (ng/ml)

<0.049

Reference

-

-

Reference

-

-

Reference

-

-

0.049–< 0.066

2.78

−3.68, 9.24

0.40

4.65

−2.89, 12.2

0.23

4.61

−2.74, 11.9

0.22

0.066–< 0.086

4.41

−2.05, 10.9

0.18

7.60

0.01, 15.2

0.050

7.31

−0.10, 14.7

0.05

≥0.086

6.18

−0.28, 12.6

0.06

9.82

1.78, 17.9

0.02

7.47

−0.58, 15.5

0.07

Isofurans (ng/ml)

<0.26

Reference

-

-

Reference

-

-

Reference

-

-

0.26–< 0.44

10.46

4.24, 16.7

0.001

8.17

1.29, 15.0

0.02

7.33

0.55, 14.1

0.03

0.44–< 0.79

5.79

−0.44, 12.0

0.07

5.05

−2.18, 12.3

0.17

5.49

−1.62, 12.6

0.13

≥0.79

11.5

5.36, 17.7

<0.001

16.4

9.10, 23.7

<0.001

14.9

7.70, 22.2

<0.001

  1. ERI defined as the weekly weight-adjusted ESA dose (units/kg/week) divided by the baseline hemoglobin level (g/dl)
  2. ESA Erythropoeisis stimulating agent, hsCRP High-sensitivity C-reactive protein
  3. a Unadjusted
  4. b Adjusted for age, sex, race, body mass index, etiology of end stage renal disease, diabetes status, transferrin saturation (serum iron/total iron binding capacity), Kt/V, serum parathyroid hormone, study visit, and treatment assignment
  5. c Adjusted for Model 2 covariates plus hsCRP
  6. d P-values obtained from comparing regression coefficients to coefficient for lowest quartile of each inflammatory marker